Kolon TissueGene Stocks Plunge 20% Ahead of TG-C Phase 3 Results
Kolon TissueGene saw its stock price plummet 20.28% on the 16th to 62,100 won, closing at a sharp decline ahead of the company's TG-C Phase 3 clinical trial results announcement scheduled for this month. The drop occurred despite intraday gains, with trading volume surging in the afternoon and price
Kolon TissueGene-29.95%
CryptoFrontier·07-19 02:09
